VANCOUVER, British Columbia--(BUSINESS WIRE)--Variational AI, the company behind Enki™, an advanced foundation model for small molecule drug discovery, today ...

Merck & Co. is taking a look at a generative AI platform. As an early user of Variational AI’s technology, the Big Pharma will assess the ability of the platform to generate novel small molecules that ...

Merck & Co. Inc., (NYSE:MRK) is one of the best conservative stocks to buy now. On September 23, the company confirmed a strategic collaboration with Variational AI to leverage its Enki Platform in ...

VANCOUVER, British Columbia, September 23, 2025--(BUSINESS WIRE)--Variational AI, Inc., a generative AI drug discovery company, today announced a collaboration with Merck, known as MSD outside of the ...

Vancouver firm's AI platform will generate chemical compounds based on Merck’s therapeutic targets. A Vancouver startup using artificial intelligence (AI) to discover new drugs has struck a deal with ...

MSD has signed an agreement with Variational AI to use its generative AI (genAI) platform Enki in the discovery of new small-molecule medicines. Vancouver, Canada-based Variational – which emerged in ...

CatDRX is a generative AI framework developed at Institute of Science Tokyo, which enables the design of new chemical catalysts based on the specific chemical reactions in which they are used. The ...